Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
PLoS One
    January 2022
  1. SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
    A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology.
    PLoS One. 2022;17:e0261181.
    >> Share

  2. HEITZ F, Lakis S, Harter P, Heikaus S, et al
    Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.
    PLoS One. 2022;17:e0262770.
    >> Share

  3. MCBRIDE CM, Campbell GP, Zhao J, Pentz RD, et al
    Applying citizen science to engage families affected by ovarian cancer in developing genetic service outreach strategies.
    PLoS One. 2022;17:e0262575.
    >> Share

  4. RUDD ML, Hansen NF, Zhang X, Urick ME, et al
    KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    PLoS One. 2022;17:e0251286.
    >> Share

  5. JUMAAH AS, Al-Haddad HS, McAllister KA, Yasseen AA, et al
    The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263585.
    >> Share

  6. ELSHAMI M, Tuffaha A, Yaseen A, Alser M, et al
    Awareness of ovarian cancer risk and protective factors: A national cross-sectional study from Palestine.
    PLoS One. 2022;17:e0265452.
    >> Share

  7. PETROCCHI S, Ongaro G, Calvello M, Feroce I, et al
    A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    PLoS One. 2022;17:e0266327.
    >> Share

  8. ANNONI AM, Longhini C
    Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    PLoS One. 2022;17:e0265387.
    >> Share

  9. DING Y, Oliveira-Ferrer L, Vettorazzi E, Legler K, et al
    VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients.
    PLoS One. 2022;17:e0269680.
    >> Share

  10. HAZAMA Y, Tsujioka T, Kitanaka A, Tohyama K, et al
    Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
    PLoS One. 2022;17:e0271245.
    >> Share

  11. DANSONKA-MIESZKOWSKA A, Szafron LA, Kulesza M, Stachurska A, et al
    PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.
    PLoS One. 2022;17:e0271539.
    >> Share

  12. ALI FT, Soliman RM, Hassan NS, Ibrahim AM, et al
    Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.
    PLoS One. 2022;17:e0272308.
    >> Share

  13. SRIRAMKUMAR S, Metcalfe TX, Lai T, Zong X, et al
    Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
    PLoS One. 2022;17:e0271584.
    >> Share

  14. HIEPP L, Mayr D, Gartner K, Schmoeckel E, et al
    Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas.
    PLoS One. 2022;17:e0271630.
    >> Share

    January 2021
  15. SATPATHY S, Patra A, Hussain MD, Kazi M, et al
    A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells.
    PLoS One. 2021;16:e0240068.
    >> Share

  16. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
    Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    PLoS One. 2021;16:e0235025.
    >> Share

  17. YUK JS, Lee B, Kim K, Kim MH, et al
    Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
    PLoS One. 2021;16:e0250723.
    >> Share

  18. ZHANG R, Yang X, Roque DM, Li C, et al
    A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
    PLoS One. 2021;16:e0240145.
    >> Share

  19. ZHANG L, Hu C, Huang Z, Li Z, et al
    In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
    PLoS One. 2021;16:e0250717.
    >> Share

  20. TOKUNAGA H, Iida K, Hozawa A, Ogishima S, et al
    Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    PLoS One. 2021;16:e0236907.
    >> Share

  21. PRAHM KP, Hogdall CK, Karlsen MA, Christensen IJ, et al
    MicroRNA characteristics in epithelial ovarian cancer.
    PLoS One. 2021;16:e0252401.
    >> Share

  22. WALSH CS, Kamrava M, Rogatko A, Kim S, et al
    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PLoS One. 2021;16:e0252665.
    >> Share

  23. OYAMA Y, Shigeta S, Tokunaga H, Tsuji K, et al
    CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    PLoS One. 2021;16:e0251079.
    >> Share

  24. GUI T, Yao C, Jia B, Shen K, et al
    Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    PLoS One. 2021;16:e0253136.
    >> Share

  25. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Wayne Novotny G, Hogdall CK, et al
    Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2021;16:e0255142.
    >> Share

  26. PARIS EA, Bahr JM, Bitterman P, Basu S, et al
    Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    PLoS One. 2021;16:e0255007.
    >> Share

  27. WANG H, Ye F, Zhou C, Cheng Q, et al
    High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
    PLoS One. 2021;16:e0245733.
    >> Share

  28. ALKHARUSI A, AlMuslahi A, AlBalushi N, AlAjmi R, et al
    Connections between prolactin and ovarian cancer.
    PLoS One. 2021;16:e0255701.
    >> Share

  29. CIRILLO PDR, Margiotti K, Fabiani M, Barros-Filho MC, et al
    Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection.
    PLoS One. 2021;16:e0255804.
    >> Share

  30. STEFANOU DT, Bamias A, Episkopou H, Kyrtopoulos SA, et al
    Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer.
    PLoS One. 2021;16:e0256051.
    >> Share

  31. MCCORKLE JR, Gorski JW, Liu J, Riggs MB, et al
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
    PLoS One. 2021;16:e0254205.
    >> Share

  32. JAREID M, Snapkov I, Holden M, Busund LR, et al
    The blood transcriptome prior to ovarian cancer diagnosis: A case-control study in the NOWAC postgenome cohort.
    PLoS One. 2021;16:e0256442.
    >> Share

  33. NAPOLI E, Bonsdorff TB, Jorstad IS, Bruland OS, et al
    Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.
    PLoS One. 2021;16:e0248133.
    >> Share

  34. HANNA DH, R Saad G
    Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles.
    PLoS One. 2021;16:e0258115.
    >> Share

  35. HO PJ, Yeoh YS, Miao H, Lim SH, et al
    Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
    PLoS One. 2021;16:e0250102.
    >> Share

  36. MIMOUN C, Paoletti X, Gaillard T, Crestani A, et al
    Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group.
    PLoS One. 2021;16:e0258783.
    >> Share

  37. ANCHOORI RK, George L, Tseng SH, Lam B, et al
    Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
    PLoS One. 2021;16:e0256937.
    >> Share

  38. SAAVALAINEN L, Lassus H, But A, Gissler M, et al
    Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study.
    PLoS One. 2021;16:e0253270.
    >> Share

  39. KAUR P, Nagar S, Bhagwat M, Uddin M, et al
    Activated heme synthesis regulates glycolysis and oxidative metabolism in breast and ovarian cancer cells.
    PLoS One. 2021;16:e0260400.
    >> Share

  40. WONG DH, Mardock AL, Manrriquez EN, Lai TS, et al
    Trends in extent of surgical cytoreduction for patients with ovarian cancer.
    PLoS One. 2021;16:e0260255.
    >> Share

  41. SAEED-VAFA D, Marchion DC, McCarthy SM, Hakam A, et al
    Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.
    PLoS One. 2021;16:e0256615.
    >> Share

  42. GRESSEL GM, Usyk M, Frimer M, Kuo DYS, et al
    Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers.
    PLoS One. 2021;16:e0259188.
    >> Share

    January 2020
  43. MIAO R, Badger TC, Groesch K, Diaz-Sylvester PL, et al
    Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    PLoS One. 2020;15:e0227707.
    >> Share

  44. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    >> Share

  45. AYYAGARI VN, Wang X, Diaz-Sylvester PL, Groesch K, et al
    Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression-An in vitro study.
    PLoS One. 2020;15:e0228024.
    >> Share

  46. ARCHER S, Babb de Villiers C, Scheibl F, Carver T, et al
    Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study.
    PLoS One. 2020;15:e0229999.
    >> Share

  47. WEN H, Qian M, He J, Li M, et al
    Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-beta pathway.
    PLoS One. 2020;15:e0230230.
    >> Share

  48. WU W, Yu LH, Ma B, Xu MJ, et al
    Retraction: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer.
    PLoS One. 2020;15:e0231890.
    >> Share

  49. LUBORSKY J, Barua A, Edassery S, Bahr JM, et al
    Inflammasome expression is higher in ovarian tumors than in normal ovary.
    PLoS One. 2020;15:e0227081.
    >> Share

  50. CHAMBERS LM, Esakov E, Braley C, AlHilli M, et al
    Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer.
    PLoS One. 2020;15:e0228511.
    >> Share

  51. KIM KK, Turner R, Khazan N, Kodza A, et al
    Role of trypsin and protease-activated receptor-2 in ovarian cancer.
    PLoS One. 2020;15:e0232253.
    >> Share

  52. ZENG Y, Chen M, Ganesh S, Hu S, et al
    Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.
    PLoS One. 2020;15:e0232235.
    >> Share

  53. PRICE JC, Azizi E, Naiche LA, Parvani JG, et al
    Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    PLoS One. 2020;15:e0233962.
    >> Share

  54. OSTMEYER J, Lucas E, Christley S, Lea J, et al
    Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.
    PLoS One. 2020;15:e0229569.
    >> Share

  55. ANTON C, Kleine RT, Mayerhoff E, Diz MDPE, et al
    Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.
    PLoS One. 2020;15:e0229543.
    >> Share

  56. HAILU HE, Mondul AM, Rozek LS, Geleta T, et al
    Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia.
    PLoS One. 2020;15:e0230625.
    >> Share

  57. SOLDI R, Ghosh Halder T, Weston A, Thode T, et al
    The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    PLoS One. 2020;15:e0235705.
    >> Share

  58. PYEON SY, Han GH, Ki KD, Lee KB, et al
    Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.
    PLoS One. 2020;15:e0236244.
    >> Share

  59. KELM NQ, Straughn AR, Kakar SS
    Withaferin A attenuates ovarian cancer-induced cardiac cachexia.
    PLoS One. 2020;15:e0236680.
    >> Share

  60. JOHNSON SC, Chakraborty S, Drosou A, Cunnea P, et al
    Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients.
    PLoS One. 2020;15:e0230092.
    >> Share

  61. POLYMEROS K, Guttery DS, Hew R, Bishop R, et al
    Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
    PLoS One. 2020;15:e0233900.
    >> Share

  62. MITTEMPERGHER L, Piskorz AM, Bosma AJ, Michaut M, et al
    Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    PLoS One. 2020;15:e0235766.
    >> Share

  63. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    >> Share

  64. SAGLAM O, Tang Z, Tang G, Medeiros LJ, et al
    KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
    PLoS One. 2020;15:e0238477.
    >> Share

  65. SOPO M, Sallinen H, Hamalainen K, Kivela A, et al
    High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    PLoS One. 2020;15:e0241484.
    >> Share

  66. ESTERMANN M, Huang YL, Septiadi D, Ritz D, et al
    Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
    PLoS One. 2020;15:e0241500.
    >> Share

  67. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2020;15:e0243944.
    >> Share

  68. LEANDERSSON P, Akesson A, Hedenfalk I, Malander S, et al
    A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    PLoS One. 2020;15:e0240418.
    >> Share

  69. WANG Y, Tao VL, Shin CY, Salamanca C, et al
    Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.
    PLoS One. 2020;15:e0240412.
    >> Share

  70. PATRA B, Lateef MA, Brodeur MN, Fleury H, et al
    Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.
    PLoS One. 2020;15:e0244549.
    >> Share

  71. BATES M, Spillane CD, Gallagher MF, McCann A, et al
    The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    PLoS One. 2020;15:e0243715.
    >> Share

    January 2019
  72. FRAGOSO-ONTIVEROS V, Velazquez-Aragon JA, Nunez-Martinez PM, de la Luz Mejia-Aguayo M, et al
    Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
    PLoS One. 2019;14:e0222709.
    >> Share

  73. GORZELITZ J, Costanzo ES, Spencer RJ, Rumble M, et al
    Longitudinal assessment of post-surgical physical activity in endometrial and ovarian cancer patients.
    PLoS One. 2019;14:e0223791.
    >> Share

  74. AMIT A, Sabo E, Movsas A, Efrat-Tamam Y, et al
    Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?
    PLoS One. 2019;14:e0211329.
    >> Share

  75. DURAN GE, Sikic BI
    The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
    PLoS One. 2019;14:e0210879.
    >> Share

  76. MRKVICOVA A, Chmelarova M, Peterova E, Havelek R, et al
    The effect of sodium butyrate and cisplatin on expression of EMT markers.
    PLoS One. 2019;14:e0210889.
    >> Share

  77. TORRES D, Hou X, Bale L, Heinzen EP, et al
    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    PLoS One. 2019;14:e0224564.
    >> Share

  78. OLIVEIRA DNP, Carlsen AL, Heegaard NHH, Prahm KP, et al
    Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    PLoS One. 2019;14:e0225249.
    >> Share

  79. WANG F, Chen X, Yuan D, Yi Y, et al
    Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.
    PLoS One. 2019;14:e0225450.
    >> Share

  80. WAMBECKE A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, et al
    Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.
    PLoS One. 2019;14:e0225860.
    >> Share

  81. ZHAO Y, Mehta M, Walton A, Talsania K, et al
    Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas.
    PLoS One. 2019;14:e0216050.
    >> Share

  82. CHE L, Yang X, Ge C, El-Amouri SS, et al
    Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.
    PLoS One. 2019;14:e0216553.
    >> Share

  83. MARTINEZ-MAS J, Bueno-Crespo A, Khazendar S, Remezal-Solano M, et al
    Evaluation of machine learning methods with Fourier Transform features for classifying ovarian tumors based on ultrasound images.
    PLoS One. 2019;14:e0219388.
    >> Share

  84. KIM B, Won D, Lee ST, Choi JR, et al
    Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    PLoS One. 2019;14:e0217521.
    >> Share

  85. ZEH N, Schneider H, Mathias S, Raab N, et al
    Human CAP cells represent a novel source for functional, miRNA-loaded exosome production.
    PLoS One. 2019;14:e0221679.
    >> Share

  86. BISHOP MR, Huskey ALW, Hetzel J, Merner ND, et al
    A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
    PLoS One. 2019;14:e0220929.
    >> Share

  87. ANDRADE DAP, da Silva VD, Matsushita GM, de Lima MA, et al
    Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
    PLoS One. 2019;14:e0220086.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016